Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that on 22 April 2026 it bought back 31,200 H shares on the Hong Kong Stock Exchange. The transaction was executed within a price range of HKD 31.18 to HKD 31.98 per share, translating into a volume-weighted average price of HKD 31.68 and an aggregate consideration of HKD 0.99 million.

Following the repurchase, the company’s issued shares excluding treasury shares fell by 0.0229% to 135.94 million. Treasury shares increased from 246,000 to 277,200, while total issued shares remained unchanged at 136.22 million because the repurchased shares are being held in treasury and have not been cancelled.

The buy-back was made under the general mandate approved on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Including this transaction, cumulative repurchases under the mandate amount to 277,200 shares, equivalent to 0.2035% of the issued share base on the mandate date. Under Listing Rule 10.06, the company is restricted from issuing new shares or disposing of treasury shares until 22 May 2026.